Upon intravenous injection, the LOMV@PD-1 nanostructures were effectively internalized by tumor cells through LyP1 peptide-mediated targeting, and PD-1 expression was observed in tumor cells by transmitting the PD-1 plasmid to the nucleus. The gene discussed is PTPN22; the disease is neoplasm.